Lunai Bioworks Inc.(LNAI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.01
10/29/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LNAI

10/29/2026: LNAI (1-star) is currently NOT-A-BUY. Pass it for now.

Lunai Bioworks Inc. is a micro-cap, pre-clinical biotechnology company that utilizes artificial intelligence and multi-omics platforms for drug discovery, diagnostics, and biodefense. The company's main strengths lie in its proprietary computational technologies, such as BioSymetrics, and its early entry into revenue-generating defense collaborations for chemical threat assessment. Its primary investment story centers on potential upside from AI-driven drug discovery pipelines and government biosecurity contracts. However, the company faces severe risks, including minimal revenues, ongoing net losses, high clinical uncertainty, and heavy dilution vulnerability typical of micro-cap equities. It is best suited for speculative growth or momentum investors willing to accept high volatility, while market participants should closely monitor clinical milestones and defense contract expansions.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company is in a pre-commercial stage with minimal revenues and high clinical uncertainty.
Momentum investorStrong fit while signal remains positiveMicro-cap status and AI themes can drive sharp, speculative short-term price volatility.
Value investorWeak fitNegative equity, recurring losses, and lack of traditional earnings make fundamental value assessment challenging.
Dividend investorWeak fitThe company pays no dividends and reinvests or burns capital to fund basic research.
Low-risk investorWeak fitHigh price volatility, dilution risk, and pre-clinical operational nature present severe risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading float and micro-cap status lead to extreme intraday and historical price swings.
Valuation riskHighPricing is largely speculative due to minimal revenue generation and negative net income.
Competition risk (AI and biotech R&D competition)HighWell-funded biotechnology rivals frequently outpace smaller platforms in clinical trials.
Business qualityMediumProprietary AI platforms hold theoretical promise, but early-stage operations limit near-term execution visibility.
Dividend incomeLow / noneNo cash distribution or dividend payouts are available for income-focused investors.
Execution riskHighThe company relies heavily on a tiny team to successfully advance complex clinical pipelines and defense contracts.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.83M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 500.8K shares
Beta 0.36
52 Weeks Range 0.15 - 5.02
Updated Date 11/15/2026
52 Weeks Range 0.15 - 5.02
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -31.54%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 10/29/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LNAI receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
LNAI has moderate overall fundamentals (3 stars), with weak financial health, moderate growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+98.0%) is partially offset by weak cash generation (FCF margin -10173555.5%), slightly negative revenue growth (+0.0%), weak profitability (net margin -6852.0%).

Financial Health Rating

★★★★★
LNAI's financial health is weak, with the relatively strongest area being soft cash strength, including free-cash-flow generation of $-5.3B (-10173555.5% of revenue). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is LNAI's strongest growth driver at +98.0% FY2026 versus FY2025 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and free-cash-flow growth (-67070.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 3.9% and approximately 84.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 37.48% supports management-shareholder alignment.

Top 5 Institutional Investors

Ground Swell Capital, LLC 1.17%
State Street Corp 0.83%
Geode Capital Management, LLC 0.53%
Jane Street Group LLC 0.52%
Vanguard Capital Management, LLC 0.35%

Unit Economics (Per $1K Revenue)

★★★★★
LNAI generates approximately $-799 of gross profit, $-151,293 of operating income, and $-101,735,555 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
LNAI has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
BioSymetrics & Biodefense ContractsRevenues derived from multi-year defense collaborations and AI computational screening services for chemical threat assessment.This is currently the primary source of early commercial revenue, though it represents a small portion of the overall business.
Therapeutics & Diagnostics (RENB / RENC segments)Future potential milestone payments, licensing agreements, and eventual product sales from oncology vaccines and diagnostic platforms.These segments are pre-commercial and do not yet generate meaningful operating revenue.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 454.39K
Price to Sales(TTM) 15.96
Enterprise Value 454.39K
Price to Sales(TTM) 15.96
Enterprise Value to Revenue 8.74
Enterprise Value to EBITDA -7.37
Shares Outstanding 5.03M
Shares Floating 4.23M
Shares Outstanding 5.03M
Shares Floating 4.23M
Percent Insiders 37.48
Percent Institutions 3.92

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.